Menotropins (HMG)

• Research value includes FSH/LH bioassay development, receptor-signalling studies, glycoform and charge-variant characterization, urine-source and process-impurity analytics, component-ratio qualification and comparison with defined recombinant gonadotropin references
• These contexts do not establish a fertility protocol or human-use benefit for an RUO batch.

CAS

61489-71-2

Formula

Not applicable: menotropins is a variable glycoprotein-hormone mixture, so component identities and lot-specific FSH/LH bioactivity replace a single molecular formula

Molecular weight

Component-specific; no single molecular weight

Appearance

Lot- and formulation-specific lyophilized material; appearance alone cannot establish identity or gonadotropin potency

Purity

Multi-attribute lot release; a single HPLC purity percentage cannot qualify a menotropins mixture · target, verify batch COA

Storage

Store and ship the supplied RUO material only according to its batch COA, stability data and validated container-closure conditions. Do not combine instructions from US single-dose MENOPUR, which is used immediately after reconstitution, with European multidose presentations that have different formulation and in-use dating. Product-specific diluent, preservative, light protection and temperature limits are not interchangeable.

MOQ

On request

Lead time

21–45 days

Menotropins, also called human menopausal gonadotropin or hMG, is a urine-derived mixture of gonadotropin activities purified from postmenopausal donors. It is not one discrete molecule. Licensed MENOPUR contains defined International Units of FSH and LH bioactivity and may contain hCG-related activity; each glycoprotein hormone is a heterodimer with a common alpha subunit and a hormone-specific beta subunit, and the preparation contains multiple glycoforms and process-related components. CAS 61489-71-2, UNII 5Y9QQM372Q and the PubChem reference collection record identify menotropins as a mixture rather than a structure-defined compound. FDA approval attaches to named finished products, their donor controls, purification, viral-safety strategy, potency assays, formulation and labelling—not to every material labelled HMG.

• Licensed menotropins products have defined reproductive-medicine indications, such as development of multiple follicles and pregnancy in selected ovulatory women undergoing assisted reproductive technology; indications differ by product and jurisdiction
• Evidence also exists for selected male hypogonadotropic-hypogonadism or spermatogenesis contexts, particularly outside the current US MENOPUR label
• This RUO material has no approved indication and is limited to analytical, receptor-signalling, bioassay, glycoform and other laboratory research.

Menotropins contains FSH and LH-related bioactivity rather than one discrete molecule. In biological systems FSH and LH act through their respective receptors in reproductive endocrine pathways, but the response of a specific HMG material depends on component activities, glycoforms, impurities, model and protocol. A MENOPUR label describes its named finished product and monitored clinical use; it cannot define mechanism, dose, ovulation-trigger timing or compatibility for an independently supplied RUO lot.

• This RUO material is not for human administration
• Licensed menotropins require specialist selection and monitoring because risks include ovarian hyperstimulation syndrome, multiple gestation, thromboembolic events, ovarian torsion, ectopic pregnancy, spontaneous abortion and other serious reproductive complications
• Product labels contain contraindications involving pregnancy, primary ovarian failure, uncontrolled non-gonadal endocrinopathies, sex-hormone-dependent tumours, pituitary or hypothalamic tumours, unexplained uterine bleeding and certain ovarian cysts or enlargement
• Urine-derived biologics also require validated donor, adventitious-agent, impurity and immunogenicity controls
• Clinical-label incidence figures apply to the studied licensed product and population, not to an RUO batch or all HMG preparations.

Interactions reported in the literature

• No clinical combination guidance applies to this RUO material
• Fertility labels may coordinate named gonadotropin products under specialist monitoring, but this neither proves physical compatibility nor authorizes mixing or substitution
• Analytical compatibility, adsorption, dilution, assay interference and combined biological effects must be established in the intended laboratory system.

Menotropins (HMG)75 IU · WHJLP-HMG75-260512-B

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

• A meaningful menotropins COA must go beyond an HPLC purity percentage
• It should state source and manufacturing stage, FSH and LH bioactivity in IU with assay methods and traceable standards, activity ratio, protein-content method, identity of gonadotropin subunits or characteristic peptide map, glycoform or charge-profile controls where relevant, aggregates, host or donor-related impurities, residual process contaminants, bioburden and adventitious-agent strategy
• Sterility, bacterial endotoxins and particulate testing are separate finished-product claims and should appear only when validated
• A white lyophilized cake or clear solution does not establish potency or identity
• Missing IU potency, an impossible small-molecule formula, a generic 98% purity claim without method, or no donor/batch traceability are critical red flags.

Store and ship the supplied RUO material only according to its batch COA, stability data and validated container-closure conditions. Do not combine instructions from US single-dose MENOPUR, which is used immediately after reconstitution, with European multidose presentations that have different formulation and in-use dating. Product-specific diluent, preservative, light protection and temperature limits are not interchangeable.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

• Primary identity and product sources: PubChem's menotropins reference collection record for mixture status, CAS 61489-71-2, UNII 5Y9QQM372Q and subunit architecture; current DailyMed MENOPUR labelling for the licensed US product's composition, bioassays, indication, storage, risks and pharmacokinetics; the current UK SmPC for its distinct multidose presentation. Evidence sources include randomized comparisons of highly purified hMG and recombinant FSH, the Cochrane review, ESHRE ovarian-stimulation guidelines and the male hypogonadotropic-hypogonadism systematic review. These clinical sources describe regulated medicines and monitored patients, not the quality or use of this RUO material.

1. 01

   A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

   Fertility and Sterility · 2012 · randomized controlled trial (multicenter, assessor-blind, noninferiority)

   Open source
2. 02

   Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection

   Fertility and Sterility · 2020 · randomized controlled trial (multicenter, assessor-blinded, noninferiority) — the MEGASET-HR trial

   Open source
3. 03

   Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles

   Cochrane Database of Systematic Reviews · 2011 · Cochrane systematic review and meta-analysis

   Open source
4. 04

   Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis

   Reproductive BioMedicine Online · 2008 · meta-analysis of randomized controlled trials

   Open source
5. 05

   Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial

   Fertility and Sterility · 2002 · randomized controlled trial (multinational phase III)

   Open source
6. 06

   Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis

   Human Reproduction Open · 2019 · systematic review and meta-analysis

   Open source
7. 07

   ESHRE guideline: ovarian stimulation for IVF/ICSI

   Human Reproduction Open · 2020 · clinical practice guideline (professional society, ESHRE)

   Open source
8. 08

   ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025

   Human Reproduction · 2026 · clinical practice guideline update (professional society, ESHRE)

   Open source